Pharmacogenetics of human androgens and prostatic diseases

Pharmacogenomics

Volumn 2, Issue 1, 2001, Pages 65-72

  Novelli, G ^a   Margiotti, K ^a   Sangiuolo, F ^a   Reichardt, J K V ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Androgen receptor; Benign prostatic hypertrophy; Chemoprevention; Finasteride; Personalised medicine; Pharmacogenetics; Prostate cancer; Single nucleotide polymorphism (SNP); Steroid 5 reductase (SRD5A2); Treatment

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; DNA; GLUCOCORTICOID; HYDROXYFLUTAMIDE; STEROID 5ALPHA REDUCTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BIOCHEMISTRY; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; GENE LOCUS; GENETIC CODE; HUMAN; HUMAN GENETICS; MALE; MEDICAL LITERATURE; MEDICINE; MOUSE; NONHUMAN; PHARMACOGENETICS; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PUBLIC HEALTH; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM; WESTERN HEMISPHERE;

FINASTERIDE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0034940666     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.2.1.65     Document Type: Review

References (53)

1. Epidemiologic of prostate cancer and bladder cancer: An overview
2. Origin, distribution and risk of benign prostatic hypertrophy
3. Cancer statistics, 2000
4. Medical therapy for benign prostatic hyperplasia: A review of the literature
5. Hereditary prostate cancer: Epidemiologic and clinical features
6. Genetic susceptibility of benign prostatic hyperplasia
7. Epidemiologic evidence regarding predisposing factors to prostate cancer
8. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer
9. The role of steroid hormones in prostate carcinogenesis
10. Prostatic growth: New insights into hormonal regulation
11. Hormonal carcinogenesis
12. Endocrinology of the prostate
13. Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility
14. The androgen receptor in prostate cancer
15. Molecular genetics of steroid 5 α-reductase 2 deficiency
16. Steroid 5α-reductase: Two genes/two enzymes
17. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals
18. Genetic variability of the human SRD5A2 gene: Implications for prostate cancer risk
19. The epidemiology of the prostate cancer. Part I: Descriptive epidemiology
20. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase
21. Association of missense substitution in the SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles
22. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)
23. Evidence for an association between the SRD5A2 (Type II steroid 5α-reductase) locus and prostate cancer in Italian patients
24. Biochemical and pharmacogenetic dissection of human steroid 5α-reductase Type II
25. Chemoprevention of prostate cancer: The prostate cancer prevention trial
26. Biochemical characterisation of SRD5A2 gene polymorphisms found in benign prostatic hyperplasia (BHP)
27. Hereditary cancer, oncogenes and anti-oncogenes
28. Molecular genetics of prostate cancer
29. Somatic mutations at the SRD5A2 locus encoding prostatic steroids 5α-reductase during prostate cancer progression
30. Androgen receptor gene mutations in prostate cancer
31. Molecular defects of the androgen receptor
32. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function
33. Reduced androgen receptor gene expression with first exon CAG repeat expansion
34. Polymorphic repeats in the androgen receptor gene: Molecular markers of prostate cancer risk
35. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer
36. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer
37. Androgen receptor CAG repeat lengths in prostate cancer: Correlation with age of onset
38. CAG repeat length in the androgen receptor gene is related to age at prostate cancer diagnosis and response to endocrine therapy, but not of prostate cancer
39. The androgen receptor gene GGN microsatellite and prostate cancer risk
40. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: A population-based control-study in china
41. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression
42. Two percent of Finnish prostate cancer patients have a germline mutation in the hormone-binding domain of the androgen receptor gene
43. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia
44. Androgen receptor CAG repeat length polymorphism in benign prostatic hyperplasia (BPH): Correlation with adenoma growth
45. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia
46. Hormone-regulated apoptosis results from re-entry of differentiated prostate cells onto a defective cell cycle
47. Update of the androgen receptor gene mutations database
48. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor
49. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA Pca 2A
50. Establishment of two human prostate cancer cell lines derived from a single bone metastasis
51. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate
52. Hormone status selects for spontaneous somatic androgen receptor variants demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer
53. Association of SRD5A2 genotype and pathological characteristics of prostate tumors